masthead-news

News & Events

Categories

Reset Categories

Filter by Topics

AACR AMP ASCO Biomarker Discovery Bristol-Myers Squibb CDx Centre Leon Berard Clinical Biomarker CMDCAS Conference Conference Call Daiichi Sankyo Durviz ESHG FFPE Financial Results Forums Gamidor Genomeweb HTG HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq DLBLCL Cell of Origin Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq System HTGEdgeSeq IAP IHC Illumina Immuno-Oncology ISO 13485 IVD Merck KGaA Molecular Profiling Nasdaq Nature Research Custom Media Webcast Nature.com NGS NSCLC Patents Platform comparison PMWC Presentation QIAGEN Reports RNA-Seq Sequencing Symposium Thermo Fisher Transcriptome VERI/O Laboratory Services Webinar WIN Consortium WIN Symposium
Reset Filter Reset All

HTG Molecular Diagnostics Provides Regulatory Update for its HTG EdgeSeq ALKPlus Assay

TUCSON, Ariz., Sept. 11, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced that it expects to complete and file the fourth and final module related to the premarket approval application (PMA) submission for its HTG EdgeSeq ALKPlus Assay in the second quarter of 2018. The first three modules of the PMA have already been submitted to the U.S. Food and Drug Administration (FDA) for review.

Read More

Posted on:
 

HTG Molecular Diagnostics Obtains CE Mark for its HTG EdgeSeq ALKPlus Assay EU

TUCSON, Ariz., March 22, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it has obtained CE marking in the European Union for its HTG EdgeSeq ALKPlus Assay EU.

The HTG EdgeSeq ALKPlus Assay EU is an in vitro diagnostic assay intended to measure and analyze mRNA ALK gene rearrangements in formalin-fixed, paraffin-embedded lung tumor specimens from patients previously diagnosed with non-small cell lung cancer (NSCLC). The assay may be used to aid in the identification of patients eligible for treatment with ALK-targeted therapeutics, such as crizotinib, and is automated on the HTG EdgeSeq system using a next-generation sequencer for detection.

Read More

Posted on:
 

HTG Molecular Diagnostics Completes Module Three Filing for HTG EdgeSeq ALKPlus Assay PMA

TUCSON, Ariz., Jan. 05, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments and reagents for molecular profiling applications, today announced that it has submitted to the FDA the third of four expected modules for the Company’s Pre-Market Approval (PMA) application for the HTG EdgeSeq ALKPlus Assay to be used as a companion diagnostic for Crizotinib.

Read More

Posted on:

Page last updated March 20, 2023